Navigation Links
Nationwide Awards Recognize Nurses, Associates and Nursing Teams That Specialize in Gastroenterology and Endoscopy
Date:3/26/2008

Recipients of 'Proud to be GI Awards' Honored for Commitment to Patient

Care

CINCINNATI, March 26 /PRNewswire/ -- Today, Procter and Gamble Pharmaceuticals (P&G) is encouraging GI and Endoscopy professionals to recognize outstanding nurses and associates for their dedication to their field and patients through its support of the Society of Gastroenterology Nurses and Associates, Inc. (SGNA) GI Nurses and Associates Day. For "GI Nurses and Associates Day," GI and Endoscopy practices across the nation are honoring nurses and associates in their local offices as a way to share the excitement that GI nurses and associates feel for the career and to draw the public's attention to individuals in the GI field.

"P&G is very proud to honor the top GI nurses and associates for the work they do," said David Lacy, GI category director at P&G Pharmaceuticals. "We are inspired by the efforts of these nurses and associates, whose professionalism and personal caring really do make a difference in the lives of their patients and the advancement of nursing. The company's support of SGNA's GI Nurses and Associates Day is part of its ongoing commitment to serve healthcare providers and patients alike."

TOP NURSES TO COMPETE FOR NEW NATIONAL AWARD

Today's award recipients were selected by their peers for their ability to demonstrate leadership, professionalism, integrity, dedication to teamwork, effective communications skills and superior clinical skills. Local winners are also eligible to be nominated for SGNA's new national "Proud to be GI" award which will be given at the SGNA's 35th Annual Course in May. Local GI offices can submit nominees through the application in the GI Nurses and Associates Day Kit -- obtained through SGNA Headquarters, http://www.sgna.org, or through their local P&G representative.

In addition to its well-known consumer brands, P&G develops and markets a gastrointestinal platform that extends across pharmaceutical and over-the- counter brands. One of these brands is Asacol(R) (mesalamine) Delayed-Release Tablets, available by prescription only, which is currently celebrating over 15 years of trusted therapy. Asacol is the No. 1 most-prescribed 5-ASA therapy for ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).(1) Additional information about Asacol can be found by visiting http://www.Asacol.com or http://www.MyUCGuide.com .

About Ulcerative Colitis

UC involves inflammation of the lining of the colon and rectum. It varies in clinical severity with patients having mild, moderate or severe disease. Treatment depends on the extent and severity of disease.

UC causes flares followed by periods of remission. During a flare, in which the rectum or colon become inflamed, people experience symptoms such as diarrhea, rectal bleeding, abdominal cramping and an urgent need to go to the bathroom. Flares can vary in duration and intensity. While UC is a lifelong condition, medication may help control flares.

UC affects people of all ages, but is often diagnosed during early adulthood. The causes of this condition are unknown, but may involve heredity, infection or the immune system.

About Asacol(R) (mesalamine) Delayed-Release Tablets 400 mg

Asacol is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).

Asacol was well-tolerated in clinical studies. Overall, the incidence of adverse events with Asacol was comparable to placebo. In pivotal clinical studies of mildly to moderately active UC, the most frequent adverse events reported for Asacol and placebo, respectively, were headache (35% vs. 36%), abdominal pain (18% vs. 14%), eructation (16% vs. 15%), pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%).

Asacol is contraindicated in patients with hypersensitivity to salicylates. Caution should be exercised when using Asacol in patients with known renal dysfunction or history of renal disease. It is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy. Serious adverse events may occur with Asacol. Please visit http://www.asacol.com/pdf/us-asacol.pdf for full prescribing information.

About Procter & Gamble (NYSE: PG)

Three billion times a day, P&G brands touch the lives of people around the world. The company has one of the strongest portfolios of trusted, quality, leadership brands, including Actonel(R), Asacol(R), Enablex(R), Prilosec OTC(R), Metamucil(R), Fibersure(R), Align(R), Pepto-Bismol(R), Vicks(R), ThermaCare(R), PUR(R), Crest(R) and Oral-B(R). The P&G community consists of over 135,000 employees working in over 80 countries worldwide. Please visit http://www.pg.com for the latest news and in-depth information about P&G and its brands.

(1) Data on file: IMS National Prescription Audit, 12 months ending May

2006.


'/>"/>
SOURCE Procter and Gamble Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
2. Nationwide Telephone News Briefing for U.S. Health Disparities Forum
3. Purifan Clean Air Wellness System Now Installed in More Than 40 Schools Nationwide
4. Nationwide to Present at Citigroup Global Property CEO Conference
5. CBS Outernet Partners With Lifeclinic International to Bring Interactive Health Programming and Advertising to Pharmacy Locations Nationwide
6. Alzheimers Foundation of America Awards Grants to Local Groups Nationwide
7. Nationwide Health Properties and Pacific Medical Buildings Join Forces in up to $2 Billion, Multi-Year Transaction
8. Press Statement: Roche Affirms That Tamiflu(R) is in Ample Supply Nationwide
9. Seven Out of 10 Americans Would Vote for a Presidential Candidate Who Supports a Nationwide Health Information Network, CSC Survey Says
10. Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site
11. Hispanic Radio Listeners Nationwide to Support Life-Saving Efforts Against Childhood Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The V Foundation for Cancer ... a Moment to Lose fundraising campaign. As the V Foundation’s boldest initiative to ... over cancer. The campaign aims to raise $200 million by 2020 and strategically ...
(Date:12/6/2016)... ... December 06, 2016 , ... Just in time for the holiday ... chocolate chip cookie recipe for Honeyville’s new Organic Quinoa Flour product for sale at ... in the near future. , “I think it’s wonderful that a growing number ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... recount of a powerful woman's story of sacrifice and enlightenment. , ... published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward writing ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has announced ... on providing occupational safety and health training to public sector employees. , “The ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... founder of Spectrum Science Communications , announced today that ... two consecutive years of high double digit growth in fee revenues. ... assumed management of the firm that Seng founded in 1996. Earlier ... of the Year and was selected among the Best Places to ... ...
Breaking Medicine Technology: